MALVERN, Pa., March 15, 2019 /PRNewswire/ -- Realm
Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical
company with a proprietary technology platform of stabilized high
concentration HOCl, announces that at the Company's general
meeting, held today in connection with the proposed Assets
Disposal to Urgo, U.S. Inc., proposed adoption of the
Investing Policy and proposed AIM Delisting, as announced in a
circular to Shareholders dated February 15,
2019 (the Circular), all Resolutions were duly passed. Proxy
figures will be displayed shortly on the Company's website
at www.realmtx.com.
Completion of the Assets Disposal is expected to occur on
March 28, 2019, assuming all
remaining conditions are met. The AIM Delisting is expected to
take effect from 7:00 a.m. (GMT) on
March 27, 2019, with the last day of
trading of the Ordinary Shares on AIM being March 26, 2019. The Company has agreed to
absorb the cost of Shareholders converting their Ordinary Shares
into American Depositary Shares (ADSs) until the date of the AIM
Delisting. Shareholders can find information on how to convert
their Ordinary Shares into ADSs on the Company's
website: www.realmtx.com in the Investors section under Events
& Presentations, Annual and General Meetings in the 2019
Circular and Schedules 1 and 2 thereto. Shareholders wishing to
convert their Ordinary Shares should ensure the relevant steps are
completed in advance of the deadline of 5
p.m. on March 18, 2019 as
noted in the Circular.
Following the cancellation of the Company's Ordinary Shares to
trading on AIM, N+1 Singer will cease to act as nominated adviser
and broker to the Company.
Capitalized terms used but not defined in this announcement
shall have the meanings given to them in the Circular.
G-RLM
About Realm Therapeutics
For more information on Realm Therapeutics, please
visit www.realmtx.com.
Forward-Looking Statements
Certain statements contained herein constitute
forward-looking statements. These forward-looking statements
reflect the Company's judgment at the date of this announcement and
are not intended to give any assurance as to future results. Except
as required by the FCA, the London Stock Exchange, the AIM Rules
for Companies or applicable law, the Company expressly disclaims
any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained in this
announcement to reflect any changes in the Company's expectations
about them or any changes in events, conditions or circumstances on
which any such statement is based.
Contacts:
Realm Therapeutics plc
Alex Martin, Chief Executive
Officer
Marella Thorell, Chief Financial
Officer and Chief Operating Officer
Outside U.S.: +44 (0) 20 3727 1000
U.S.: +1 212 600 1902
Argot Partners
Stephanie Marks / Claudia Styslinger
+1 212 600 1902
FTI Consulting
Simon Conway
+44 (0) 20 3727 1000
N+1 Singer (Nominated Adviser and Broker)
Aubrey Powell / Jen Boorer
+44 (0) 20 7496 3000
View original
content:http://www.prnewswire.com/news-releases/realm-therapeutics-announces-result-of-general-meeting-300813168.html
SOURCE Realm Therapeutics